Randomised Controlled Clinical Trials of Adtec SteriPlas/MicroPlaSter Plasma Treatment of Wounds and Dermatological conditions over a 14 year period.

Adtec Healthcare’s plasma technology has been tested in 7 randomised controlled clinical trials with proven clinical efficacy and safety. The first participant in an RCT with our plasma technology was on 24th October 2005 - This was also the first RCT worldwide to investigate the clinical efficacy of cold plasma. We continue to be actively involved in RCTs and clinical studies with SteriPlas to produce strong clinical evidence. 

The results of these trials include wound size reduction, bigger reduction of bacterial load compared to antibiotics, treatment of AK lesions and reduction of pain with no adverse events reported.

1. ACTICAP - A prospective, randomised, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel®) in patients with actinic keratoses
University Hospital Essen, Germany
Status – Trial completed 2019 and publication planned 2020

2. Prospective, Randomised and Placebo Controlled Clinical Trial (RCT) for the validation of treatment of chronic wounds with cold atmospheric plasma (CAP)
University Hospital Essen, Germany
Status – Trial completed 2018 and publication planned 2020

3. A randomised controlled trial to evaluate the efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers compared to those treated with standard of care dressings
Salford Royal Foundation Trust, UK
Leeds TeachingHospital, UK
Status – Trial ongoing

4. Low temperature argon plasma for in vivo sterilization of chronic wounds
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed 2013 and published
Successful and Safe Use of 2 Min Cold Atmospheric Argon Plasma in Chronic Wounds: Results of A Randomized Controlled Trial. Isbary ,British Journal of Dermatology, 2012.
A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients, Isbary ,British Journal of Dermatology, 2010

5. Randomised placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites
University Hospital Regensburg Germany
Status – Trial completed and published
Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Heinlin Wound Repair Reg 2013

6. Randomised placebo-controlled clinical trial showed cold atmospheric
argon plasma in herpes zoster
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published

Randomized placebo-controlled clinical trial showed cold atmospheric argon `plasma relieved acute pain and accelerated healing in herpes zoster, Isbary , Clinical Plasma Medicine,2014,

7. A randomised two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published
A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus, Heinlin, J Eur Acad Dermatol Venereol. 2013.


Can two plasma medical devices have the same clinical efficacy?

We have been asked by Health Care Professionals to clarify , “What is the difference between the Adtec SteriPlas (Adtec Healthcare) and other cold plasma technologies such as Plasma Care® ?” or “Can two different plasma technologies have the same clinical efficacy… what’s the difference?”.

The answers to these questions are that there is a significant difference between plasma technologies, and it is therefore not possible to claim a similarity in clinical efficacy as the plasma treatments would be different.

Two devices do not produce the same plasma and it is the composition of the plasma that exerts the effects, beneficial and detrimental. For the importance of patient safety, Adtec Healthcare advises against any other plasma device claiming clinical efficacy from the clinical evidence of the CE approved SteriPlas gas plasma. Adtec’s clinical data should never be used to compare to any other plasma treatment which have not yet been clinically tested.

Atmospheric pressure Plasma has a myriad of potential medical applications from low energy plasmas used for wound healing to higher energy plasmas used to cut bones during an operation or for coagulation. The main differences in all plasma technologies include the different forms of plasmas electrode source designs, types of energy used (RF, DC and microwave) and gas used (argon, helium or nitrogen etc) versus air. The Adtec SteriPlas (MicroPlaSter) plasma technology is based on a microwave powered plasma jet utilising argon gas and the other technology is a DC powered Surface Micro Discharge (SMD) plasma source utilising air as carrier gas. The type of plasma generated corresponds directly to the type of treatment delivered to the patient.  Each type of plasma delivers a specific type of treatment.

During the pre-clinical trials and studies, Max Planck had conducted a study illustrating the noticeable differences of our argon gas microwave plasma treatment vs the surface micro-discharge (SMD) ‘Air plasma’ treatment developed at MPI. In this study, clear distinctions could be observed such as argon gas plasma treatment included predictable, safe and low dosages of reactive species whereas air-based plasmas would deliver significantly higher concentrations (over 37 times more than argon microwave plasma).  Air Plasma has much higher levels of NOx and Ozone than argon gas plasma and needs to be tested not only clinically but also safety for the operator. It is essential to verify the product safety and clinical safety of these higher levels of NOx. The air-based plasmas are also generally dependent on the surrounding environment; temperature and humidity will affect the way the plasmas are generated and therefore difficult to deliver the same treatment each time the plasma is generated.

Adtec Plasma Technology has been at the forefront for the development of plasma products for over 30 years, proudly placing us as one of the leaders in the semiconductor and RF plasma market. Adtec has also developed other plasma technologies (gas and air) for remote plasma, gas abatement and surface treatment applications.

In 2002, we designed our first cold plasma technology showing painless effect on contact with human skin. This revolutionised the way how we are used to dealing with plasmas – typically sought as too hot to touch but now redesigned to be colder and harmless on contact with skin. In 2004, our research results were presented at a plasma conference showing distinctive microbial load reduction was possible when bacteria were exposed to our gas plasma.

Later in 2004, Adtec introduced this plasma technology to the Max Planck Institute for Extraterrestrial Physics leading to a collaboration in plasma medicine. The Adtec plasma source was adapted to a wide area plasma source in collaboration with MPI.  This plasma source of the medical device is a shared patent with Adtec and MPI (as seen in the image below). This plasma source is one of the critical components used in the SteriPlas and MicroPlaSter. Adtec solely and exclusively designed and developed the medical device prototypes and products including customized components, electrical, mechanical and software program satisfying the strict standards of European medical device regulations.

We are grateful to the plasma medicine team at Max Planck for having an interest in our plasma technology system, for carrying out extensive scientific research and for managing the clinical trials using the Adtec MicroPlaSter. These clinical trials placed our medical device as the first worldwide to be used in clinical trials on wounds, paving a new treatment programme that would later be adopted by other companies with an interest to develop gas plasma medical devices.  The extensive research and clinical testing assure us of the safety of the product and the technology.

The new European MDR regulations coming into force next year also require all companies to produce proper clinical evidence to support their product claims. We do emphasize the importance of proper pre-clinical and clinical testing of all types of plasma technologies in order to be assured of the product and clinical safety. Adtec Healthcare do encourage and support plasma companies in this industry as our goal is to make gas plasma a recognised treatment option for patients with wounds, surgical site infections and dermatological conditions.


Growing media coverage of Adtec's plasma research project with Cranfield University

We’re excited to see growing media coverage of our recent post on our plasma research project with Cranfield University.

You can see the article on @CranfieldUni ‘s page: https://www.cranfield.ac.uk/press/news-2019/students-research-cleaning-solar-collectors-without-water#.XREueOGrOlc.email

It can also be found on @Solar_And_Power’s page: https://solarpowermanagement.net/article/107599/Students_Research_Cleaning_Solar_Collectors_Without_Water

And @NACleanEnergy ‘s page: http://www.nacleanenergy.com/articles/34831/students-research-cleaning-solar-collectors-without-water

The focus of this research is to understand the utilisation of plasma-assisted surface conditioning of low-iron glass solar reflecting mirrors for concentrating solar thermal power applications. The research project is supervised by leading experts in this field Professor Chris Sansom and Dr Peter King of Cranfield University and Dr Adam Bennett of Cranfield Plasma Solutions.

Currently much water is used to clean the mirrors, a precious resource in arid terrains. The aim of this project is to investigate the characteristics of a novel atmospheric pressure plasma system used to condition CSP concentrating mirrors which will be capable of reducing the amount of water used in the cleaning process.

#CSP #concentratingsolarpower #solarpower #solar #solarenergy
#renewableenergy #greenenergy #energy #cleanenergy #sustainableenergy #sustainablepower
#sustainableenvironment #gasplasma #airplasma


Adtec Plasma in CSP Renewable Energy Project

Adtec Europe Ltd is sponsoring two post-graduate students to do research in new potential applications for plasma in collaboration with Cranfield University.

The focus of this research is to understand the utilisation of plasma-assisted surface conditioning of low-iron glass solar reflecting mirrors for concentrating solar thermal power applications. The research project is supervised by leading experts in this field Professor Chris Sansom and Dr Peter King of Cranfield University and Dr Adam Bennett of Cranfield Plasma Solutions.

CSP plants generate electricity by concentrating sun light with large arrays of mirrors which are usually located in desert regions. Consequently, the mirrors get covered in sand and dust, and require cleaning with brushes and water on a regular basis. Currently much water is used to clean the mirrors, a precious resource in arid terrains. The aim of this project is to investigate the characteristics of a novel atmospheric pressure plasma system used to condition CSP concentrating mirrors which will be capable of reducing the amount of water used in the cleaning process.

The Global Concentrating Solar Power (CSP) market was valued at over $3 Billion US in 2016 and is anticipated to grow by 13% by 2025. There is also a compelling business desire to undertake this project. The development of a novel atmospheric pressure plasma system will be a significant game changer in the CSP market. Such a disruptive technology is anticipated to yield significant commercial benefits.

#CSP #concentratingsolarpower #solarpower #solar
#solarenergy #renewableenergy #greenenergy #energy #cleanenergy #sustainableenergy
#sustainablepower #sustainableenvironment #plasma #gasplasma #coldplasma
#kaltesplasma #airplasma


Poster presentation at the International Symposium on the Diabetic Foot Conference, Hague.

Wednesday 22nd May 2019

A great poster presentation from Dr Aye Aye Thant at the ISDF 2019 conference!

Dr Thant’s presentation demonstrated the benefits of using the Adtec SteriPlas on diabetic foot ulcer patients.

Prior to the use of the Adtec SteriPlas, all patients in their retrospective study suffered from chronic and non-healing foot and leg ulcers with multi resistant bacteria and recalcitrance to antibiotics. All patients had at least 3 courses of intravenous antibiotics for more than 6 weeks prior with poor response.

The Adtec SteriPlas was then introduced as a treatment option. Instantly, positive results could be seen with the infection management for these patients. For example, one patient who was previously considered for an amputation was now improved and risk free. Healthy granulation could be observed with all patients, offering hope and an alternative to antibiotics that would usually be offered.

For more information on the Adtec SteriPlas, visit our website www.adtecplasma.com or send us an email at info@adtec.eu.com


Mr Keith Cutting presents significant results on DFUs in Vienna conference

Mr Keith Cutting presented at The European Conference on Controversies in Diabetic Foot Management conference in Vienna last week. His presentation focused on the benefits of treating complex diabetic foot ulcer patients with the Adtec SteriPlas.

The Adtec SteriPlas has shown promising results leading to healing in problematic and non-healing wounds such as diabetic foot ulcers or surgical site infections. These complex wounds that have shown signs of stalled healing respond well to intervention with the Adtec SteriPlas.

To learn more about our medical device and the benefits it offers to patients with wounds, surgical site infections and dermatological conditions send us an email at info@adtec.eu.com


Gas plasma shows promising results in the treatment of non-healing wounds

Renowned for its ability to successfully treat non-healing wounds, the Adtec SteriPlas is a must have for any dermatology and wound care departments.

This 61-year-old patient with a long-term venous ulcer was stalled from healing and present with Klebsiella oxytoca and Enterobacter cloacae. The patient went through a short treatment programme with our gas plasma medical device to achieve exceptional results. Figures (a) - (b) shows the visual changes of the ulcer throughout the short course of treatment with the Adtec SteriPlas.

Figure (a) shows the patient's ulcer at the start of the treatment
Figure (b) shows after 7 applications of our gas plasma.
Figure (c) shows after 11 treatments of our gas plasma.

At the end of the treatment programme, swabs which would normally have shown signs of bacteria were now sterile, allowing the patient to further progress into full healing.

Interested to hear more? Reach out to us at info@adtec.eu.com


Surgical site infections treated with the Adtec SteriPlas

Surgical site infections (SSIs) are still a severe complication after cardiac surgery with a mortality estimated range of up to 40% of cases. These post-operative wounds are generally associated with longer hospital stay and the delayed or inadequate therapeutic measures can lead to avoidable hospital costs for the healthcare system. The significant cost burden on the hospital for a single SSI case is €36,000. 1

It has already been shown that the Adtec SteriPlas is effective due to its increased penetration depth in SSIs to defeat bacteria even under a layer of biofilm independently to their resistance profile. This includes multi-resistant bacteria that have shown little or no response to antibiotics previously. In combination with advanced negative pressure wound treatment (aNPWT), the Adtec SteriPlas has been praised as a “tissue saving approach” offering patients a favourable treatment method for these complicated and chronic wounds compared to conventional treatment therapies. 2

Studies conducted using the Adtec SteriPlas have shown a significant decrease in the mortality rate coupled with accelerated healing. Patients with infected drivelines such as those with left ventricular assist devices have healed in as quick as 1 week, and patients with sternal SSIs have healed in as quick as 6 days. 2,3

The table above shows Dr H. Rotering’s recent data presented at the Chirurgie 2019 conference. The table explains that patients with infected drivelines have healed in as quick as 1 minute.

Both patients and doctors have praised the Adtec SteriPlas for its exceptional ability at delivering promising results leading to healing.

Be sure to contact us for more information and to see how our medical device may benefit your patients.

  1. H. Rotering, Cold atmospheric plasma – New options for infection control in wound management, EWMA 2016.
  2. H. Rotering, Cold atmospheric plasma and advanced Negative Pressure Wound Treatment – First results of a tissue saving approach for deep surgical site infections, EACTS 2018.
  3. H. Rotering, Das infizierte Implantat, Komplexe Wundbehandlung – Kaltes atmospherisches Plasma und advanced NPWT in der Herzchirurgie, Chirurgie 2019.

Promising results for the treatment of diabetic foot ulcers using the Adtec SteriPlas

We are excited to show you a recent conference poster presented at the BSAC Spring 2019 conference, submitted by Kettering General Hospital NHS Foundation Trust.

The poster shows the promising results of the using the Adtec SteriPlas on diabetic foot ulcers that are stalled by biofilm. The SteriPlas “is postulated as an alternative for antibiotics for patients where antibiotic therapy is difficult (due to resistance or adverse effects) or as an adjunct treatment for patients with chronic wounds including those with biofilms”.

Contact us at info@adtec.eu.com to learn more about how the Adtec SteriPlas may benefit your non-healing wound patients.


Adtec receive funding to conduct a clinical biofilm project in UK Hospital

Adtec Healthcare is delighted to announce that we will start a project to measure the ‘Efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers’ in August 2016. The project will be a collaboration between Salford Royal NHS Foundation Trust, leading UK wound care experts, University Hospital Jena Germany and Adtec. The project is co-funded by the UK’s Innovation agency, Innovate UK and Adtec.


Read more